PaulAFrohnaMDPhD, PharmD
Research • Solana Beach, CAChief Medical & Scientific Officer, ImCheck Therapeutics (Marseille, FRANCE) Developing drugs for immuno-oncology, infectious diseases and autoimmune disorders.
Dr. Frohna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Marseille, France
Solana Beach, CA 92075- Is this information wrong?
Summary
- Paul Frohna, MD, PhD, is a researcher in Marseille, France. He received his medical degree from Georgetown University School of Medicine and has been doing clinical research for 20 years. He does not see patients. He is experienced in translational medicine and clinical trials in immuno-oncology, immunology, multiple sclerosis, Alzheimer's disease and regenerative medicine.
Education & Training
University of Texas at Austin Dell Medical SchoolInternship, Internal Medicine, 2000 - 2001
Georgetown University School of MedicineClass of 2000
Clinical Trials
- U.S. Study of Fibrocaps in Surgical Hemostasis Start of enrollment: 2010 Dec 01
- A Study of Fibrocaps in Liver Surgery in the Netherlands Start of enrollment: 2010 Dec 01
- A Study of Fibrocaps™ in Surgical Bleeding Start of enrollment: 2012 May 21
- Join now to see all
Publications & Presentations
PubMed
- 29 citationsEfficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study:Jeffrey A. Cohen, Giancarlo Comi, Douglas L. Arnold, Amit Bar-Or, Krzysztof Selmaj, Lawrence Steinman, Eva Havrdova, Bruce A.C. Cree, Xavier Montalban, Hans-Peter Hart...> ;Multiple Sclerosis. 2019 Aug 1
- 145 citationsRPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.Ikuo Hirano, Margaret H. Collins, Yehudith Assouline-Dayan, Larry Evans, Sandeep K. Gupta, Alain M. Schoepfer, Alex Straumann, Ekaterina Safroneeva, Michael Grimm, Hea...> ;Gastroenterology. 2019 Feb 1
- 31 citationsCardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.Jonathan Q. Tran, Jeffrey P. Hartung, Allan Olson, Boaz Mendzelevski, Gregg Timony, Marcus F. Boehm, Robert Peach, Sheila Gujrathi, Paul A. Frohna> ;Clinical Pharmacology in Drug Development. 2018 Mar 1
- Join now to see all
Press Mentions
- ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual MeetingNovember 11th, 2022
- Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022September 10th, 2022
- ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021September 17th, 2021
- Join now to see all
External Links
- Frohna Biotech Consultinghttp://www.frohnabiotechconsulting.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
